Shamburg News · 8-K filed Nov 4, 2026, 7:30 AM EST
Arrowhead Refinances $400 Million Sixth Street Term Loan at SOFR Plus 5.50%, Extends Maturity to 2031
ARWR · ARROWHEAD PHARMACEUTICALS, INC.
- Material agreement
- Financing
- Financial statements
- Materiality: high
Arrowhead Pharmaceuticals entered into an Amended and Restated Financing Agreement on November 2, 2026 for a $400.0 million senior secured term loan maturing November 2, 2031, bearing interest at three-month Term SOFR plus 5.50%. The company used cash on hand to repay the existing term loans, with an aggregate payoff of approximately $404.4 million, reflecting a discount of approximately $68 million from the contractual MOIC payment. The company also disclosed the transaction in an earnings-related press release dated November 4, 2026, which described the refinancing and reported fiscal 2026 results for the period ended September 30, 2026.
Source: SEC EDGAR, Form 8-K, Items 1.01, 2.03, accession 0000879407-26-000063.
Written from the filing by Shamburg Markets. Figures are as reported by the company.